JFS Wealth Advisors
ACAD icon

JFS Wealth Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History

JFS Wealth Advisors’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.79K Hold
89
– – ﹤0.01% 1630
2026
Q2 		$2.25K Buy
89
+20
+29% +$440 ﹤0.01% 1568
2026
Q1 		$1.54K Sell
69
-3
-4% -$72 ﹤0.01% 1582
2025
Q4 		$1.92K Buy
72
+35
+95% +$836 ﹤0.01% 1557
2025
Q3 		$790 Buy
37
+7
+23% +$166 ﹤0.01% 1671
2025
Q2 		$648 Buy
+30
New +$558 ﹤0.01% 1650

Other funds holding ACAD

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $64.1B AUM 28.9% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $91.6B AUM 30% 1-Year Est. Return
Y-Intercept (HK)
Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

JFS Wealth Advisors's ACAD Position: Q3 2026 in Review

JFS Wealth Advisors held its Acadia Pharmaceuticals (ACAD) position steady in Q3 2026 at 89 shares worth $1.79K. The position accounts for ﹤0.01% of the portfolio, ranked #1630.

JFS Wealth Advisors first reported a position in ACAD in Q2 2025 and has held it in 6 quarters since. The position peaked at $2.25K in Q2 2026. 137 funds tracked by Wall St. Rank hold ACAD as of Q3 2026.

  • JFS Wealth Advisors held 89 shares of Acadia Pharmaceuticals worth $1.79K as of Q3 2026.
  • JFS Wealth Advisors left its Acadia Pharmaceuticals share count unchanged in Q3 2026.
  • Acadia Pharmaceuticals made up ﹤0.01% of JFS Wealth Advisors's portfolio in Q3 2026, its #1630 holding.
  • JFS Wealth Advisors first reported a position in Acadia Pharmaceuticals in Q2 2025 and has held it in 6 quarters since.
  • JFS Wealth Advisors's Acadia Pharmaceuticals position peaked at $2.25K in Q2 2026.
  • 137 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2026.

Based on JFS Wealth Advisors's 13F filing for Q3 2026, filed 3 Nov 2026.